$ANIK
Anika Therapeutics, Inc.

2019 Q1 Form 10-Q Financial Statement

#000117184319002946 Filed on May 06, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $24.72M $21.26M
YoY Change 16.27% -9.07%
Cost Of Revenue $7.311M $7.845M
YoY Change -6.81% 28.97%
Gross Profit $17.41M $13.41M
YoY Change 29.81% -22.46%
Gross Profit Margin 70.43% 63.08%
Selling, General & Admin $7.672M $16.09M
YoY Change -52.32% 217.54%
% of Gross Profit 44.06% 119.96%
Research & Development $4.258M $5.161M
YoY Change -17.5% 22.01%
% of Gross Profit 24.45% 38.48%
Depreciation & Amortization $1.480M $1.470M
YoY Change 0.68% 45.54%
% of Gross Profit 8.5% 10.96%
Operating Expenses $11.93M $21.25M
YoY Change -43.86% 128.58%
Operating Profit $5.482M -$7.832M
YoY Change -169.99% -197.83%
Interest Expense $498.0K $95.00K
YoY Change 424.21% 63.79%
% of Operating Profit 9.08%
Other Income/Expense, Net
YoY Change
Pretax Income $5.980M -$7.737M
YoY Change -177.29% -195.94%
Income Tax $1.473M -$1.051M
% Of Pretax Income 24.63%
Net Earnings $4.507M -$6.686M
YoY Change -167.41% -221.72%
Net Earnings / Revenue 18.23% -31.44%
Basic Earnings Per Share $0.32 -$0.46
Diluted Earnings Per Share $0.31 -$0.46
COMMON SHARES
Basic Shares Outstanding 14.19M 14.68M
Diluted Shares Outstanding 14.31M 14.68M

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $166.7M $163.0M
YoY Change 2.27% 17.6%
Cash & Equivalents $95.51M $141.8M
Short-Term Investments $71.20M $21.30M
Other Short-Term Assets $2.100M $4.100M
YoY Change -48.78% 241.67%
Inventory $22.62M $22.77M
Prepaid Expenses
Receivables $18.27M $18.29M
Other Receivables $0.00 $0.00
Total Short-Term Assets $209.7M $208.2M
YoY Change 0.72% 17.59%
LONG-TERM ASSETS
Property, Plant & Equipment $53.05M $55.77M
YoY Change -4.88% 8.1%
Goodwill $7.694M $8.452M
YoY Change -8.97% 15.34%
Intangibles $8.467M $10.68M
YoY Change -20.71% 5.08%
Long-Term Investments
YoY Change
Other Assets $4.003M $1.247M
YoY Change 221.01% 3.92%
Total Long-Term Assets $96.96M $76.15M
YoY Change 27.33% 8.29%
TOTAL ASSETS
Total Short-Term Assets $209.7M $208.2M
Total Long-Term Assets $96.96M $76.15M
Total Assets $306.7M $284.3M
YoY Change 7.85% 14.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.571M $6.159M
YoY Change -42.02% 1.8%
Accrued Expenses $8.000M $7.963M
YoY Change 0.46% 89.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.60M $14.12M
YoY Change -17.84% 38.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $366.0K $1.150M
YoY Change -68.17% 187.5%
Total Long-Term Liabilities $366.0K $1.150M
YoY Change -68.17% 187.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.60M $14.12M
Total Long-Term Liabilities $366.0K $1.150M
Total Liabilities $11.97M $15.27M
YoY Change -21.63% 43.84%
SHAREHOLDERS EQUITY
Retained Earnings $222.7M $192.8M
YoY Change 15.51% 11.34%
Common Stock $52.17M $75.11M
YoY Change -30.53% 17.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $269.1M $263.8M
YoY Change
Total Liabilities & Shareholders Equity $306.7M $284.3M
YoY Change 7.85% 14.95%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income $4.507M -$6.686M
YoY Change -167.41% -221.72%
Depreciation, Depletion And Amortization $1.480M $1.470M
YoY Change 0.68% 45.54%
Cash From Operating Activities $8.462M $9.592M
YoY Change -11.78% -37.96%
INVESTING ACTIVITIES
Capital Expenditures $1.030M $2.543M
YoY Change -59.5% 51.82%
Acquisitions
YoY Change
Other Investing Activities -$890.0K $2.750M
YoY Change -132.36% 120.0%
Cash From Investing Activities -$1.917M $207.0K
YoY Change -1026.09% -148.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -119.0K -1.223M
YoY Change -90.27% -3082.93%
NET CHANGE
Cash From Operating Activities 8.462M 9.592M
Cash From Investing Activities -1.917M 207.0K
Cash From Financing Activities -119.0K -1.223M
Net Change In Cash 6.426M 8.576M
YoY Change -25.07% -43.11%
FREE CASH FLOW
Cash From Operating Activities $8.462M $9.592M
Capital Expenditures $1.030M $2.543M
Free Cash Flow $7.432M $7.049M
YoY Change 5.43% -48.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
419000
CY2018Q4 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
577000
CY2019Q1 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
392000
CY2018Q4 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
400000
CY2019Q1 anik Accumulated Currency Translation Adjustment
AccumulatedCurrencyTranslationAdjustment
4752000
CY2018Q4 anik Accumulated Currency Translation Adjustment
AccumulatedCurrencyTranslationAdjustment
4576000
CY2019Q1 anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-269000
CY2018Q1 anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
CY2019Q1 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
26259000
CY2018Q4 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
25133000
CY2019Q1 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1
CY2018Q1 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1810000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1989000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5841000
CY2019Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8031000
CY2018Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8146000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3571000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3143000
CY2019Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18265000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20775000
CY2019Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1296000
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
385000
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2019Q1 us-gaap Assets
Assets
306659000
CY2018Q4 us-gaap Assets
Assets
278993000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
209695000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
202943000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
246000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
207000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95514000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5526000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
52030000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50763000
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
124000
CY2018Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1736000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1386000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7565000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1386000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7565000
CY2019Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1210000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1525000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89042000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133256000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141797000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6472000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8541000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14214000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14210000
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14214000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14210000
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
142000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
142000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4192000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6066000
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
67000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7311000
CY2018Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7845000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
19241000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
29096000
CY2019Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-124000
CY2018Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-75000
CY2019Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2019Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3388000
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3542000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1477000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1473000
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
46000
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-35000
CY2019Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.246
CY2018Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.136
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2563000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4446000
CY2019Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
297000
CY2018Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
CY2019Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14706000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14439000
CY2019Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-721000
CY2018Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-142000
CY2019Q1 us-gaap Goodwill
Goodwill
7695000
CY2018Q4 us-gaap Goodwill
Goodwill
7851000
CY2019Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-156000
CY2018Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2019Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
281000
CY2018Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5980000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7737000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1473000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1051000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
496000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-180000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2489000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5730000
CY2019Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
910000
CY2018Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-1478000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1928000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3270000
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1617000
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3924000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
182000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-509000
CY2019Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
28206000
CY2019Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8467000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9191000
CY2019Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
498000
CY2018Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
95000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2025000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1490000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9708000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
306659000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278993000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11602000
CY2019Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7536000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6819000
CY2019Q1 us-gaap Inventory Net
InventoryNet
22617000
CY2018Q4 us-gaap Inventory Net
InventoryNet
21300000
CY2019Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
3642000
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
3833000
CY2019Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12751000
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
13688000
CY2018Q1 us-gaap Inventory Recall Expense
InventoryRecallExpense
1100000
CY2017 us-gaap Inventory Recall Expense
InventoryRecallExpense
900000
CY2019Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5972000
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4626000
CY2019Q1 us-gaap Inventory Write Down
InventoryWriteDown
381000
CY2018Q1 us-gaap Inventory Write Down
InventoryWriteDown
3246000
CY2019Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
363000
CY2018Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
CY2019Q1 us-gaap Lease Cost
LeaseCost
576000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
23530000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1965000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1981000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2024000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11289000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
497000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23748000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.041
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P17Y219D
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
476000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
349000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4003000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4897000
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-315000
CY2019Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
71222000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
69972000
CY2019Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div></td> <td style="width: 7px">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Nature of Business</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Anika Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a global, integrated orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> decades of global expertise developing, manufacturing, and commercializing products based on its proprietary Hyaluronic Acid (&#x201c;HA&#x201d;) technology. The Company&#x2019;s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and foreign regulations and approval requirements, as well as the ability to grow the Company&#x2019;s business through appropriate commercial strategies.</div></div>
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-119000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1223000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1917000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
207000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8462000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
9592000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
4507000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-6686000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
5482000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7832000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
522000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
23307000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1075000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22232000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2018Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
620000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-315000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
620000
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
366000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
550000
CY2019Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
124000
CY2018Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1735000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
58981000
CY2018Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12500000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1030000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2543000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2077000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1854000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
58094000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15250000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
512000
CY2019Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53051000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54111000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4258000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5161000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
222740000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
218233000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24723000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21264000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
24110
CY2018Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14185000
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14679000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7672000
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16090000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1386000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7565000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y182D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y182D
CY2019Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
2000
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5000
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
512000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
269071000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
263612000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
263491000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
263766000
CY2019Q1 us-gaap Variable Lease Cost
VariableLeaseCost
52000
CY2019Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
129000
CY2018Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14314000
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14679000

Files In Submission

Name View Source Status
0001171843-19-002946-index-headers.html Edgar Link pending
0001171843-19-002946-index.html Edgar Link pending
0001171843-19-002946.txt Edgar Link pending
0001171843-19-002946-xbrl.zip Edgar Link pending
anik-20190331.xml Edgar Link completed
anik-20190331.xsd Edgar Link pending
anik-20190331_cal.xml Edgar Link unprocessable
anik-20190331_def.xml Edgar Link unprocessable
anik-20190331_lab.xml Edgar Link unprocessable
anik-20190331_pre.xml Edgar Link unprocessable
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_050319p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending